BiotechTube

COL-1620 + Gonadotropin-releasing hormone (GnRH) analogue + Follicle-stimulating hormone (FSH) + Human Chorionic Gonadotropin (hCG)

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Luteal Hormone Supplementation in In-vitro Fertilization

Conditions

Luteal Hormone Supplementation in In-vitro Fertilization, Embryo Transfer

Trial Timeline

Jul 1, 2013 → Oct 1, 2014

NCT ID
NCT01863680

About COL-1620 + Gonadotropin-releasing hormone (GnRH) analogue + Follicle-stimulating hormone (FSH) + Human Chorionic Gonadotropin (hCG)

COL-1620 + Gonadotropin-releasing hormone (GnRH) analogue + Follicle-stimulating hormone (FSH) + Human Chorionic Gonadotropin (hCG) is a phase 3 stage product being developed by Merck for Luteal Hormone Supplementation in In-vitro Fertilization. The current trial status is completed. This product is registered under clinical trial identifier NCT01863680. Target conditions include Luteal Hormone Supplementation in In-vitro Fertilization, Embryo Transfer.

What happened to similar drugs?

1 of 1 similar drugs in Luteal Hormone Supplementation in In-vitro Fertilization were approved

Approved (1) Terminated (0) Active (0)
✅progesterone + ProgesteroneMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01863680Phase 3Completed

Competing Products

1 competing product in Luteal Hormone Supplementation in In-vitro Fertilization

See all competitors
ProductCompanyStageHype Score
progesterone + ProgesteroneMerckApproved
39